US Patent

US11998526 — Methods of improving renal function

Method of Use · Assigned to Chinook Therapeutics Inc · Expires 2040-12-16 · 15y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of improving kidney function in a subject.

USPTO Abstract

Provided herein are methods of improving kidney function in a subject in need thereof.

Drugs covered by this patent

atrasentan-hydrochloride (ATRASENTAN HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3980`	—	atrasentan-hydrochloride

Patent Metadata

Patent number: US11998526
Jurisdiction: US
Classification: Method of Use
Expires: 2040-12-16
Drug substance claim: No
Drug product claim: No
Assignee: Chinook Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.